These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17472420)

  • 1. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
    Boshier A; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2003 Dec; 59(10):767-73. PubMed ID: 14615857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
    Davies M; Wilton L; Shakir S
    Drug Saf; 2013 Apr; 36(4):237-46. PubMed ID: 23483377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    J Psychopharmacol; 2007 Jun; 21(4):392-9. PubMed ID: 17656426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
    Kasliwal R; Wilton LV; Shakir SA
    Drug Saf; 2008; 31(10):839-50. PubMed ID: 18759508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
    Wilton LV; Shakir S
    Epilepsia; 2002 Sep; 43(9):983-92. PubMed ID: 12199723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Clarke A; Wilton LV; Shakir SA
    Osteoporos Int; 2005 May; 16(5):490-500. PubMed ID: 15309382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
    Davies M; Wilton LV; Shakir SA
    Drug Saf; 2008; 31(4):313-23. PubMed ID: 18366242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England.
    Wilton LV; Shakir SA
    Drug Saf; 2002; 25(3):213-23. PubMed ID: 11945116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.
    Osborne V; Hazell L; Layton D; Shakir SA
    Drug Saf; 2010 Mar; 33(3):213-21. PubMed ID: 20158285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.
    Marshall V; Wilton L; Shakir S
    Acta Diabetol; 2006 May; 43(1):6-13. PubMed ID: 16710643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
    Perrio MJ; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(8):681-95. PubMed ID: 17696581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.
    Buggy Y; Cornelius V; Fogg C; Kasliwal R; Layton D; Shakir SA
    Drug Saf; 2013 Jul; 36(7):521-31. PubMed ID: 23657823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
    Barrera BA; Wilton L; Harris S; Shakir SA
    Osteoporos Int; 2005 Dec; 16(12):1989-98. PubMed ID: 16133643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction.
    Maclennan KM; Boshier A; Wilton LV; Shakir SA
    BJU Int; 2006 Jul; 98(1):125-31. PubMed ID: 16831156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.
    Perrio MJ; Wilton LV; Shakir SA
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):969-78. PubMed ID: 17476703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.
    Hazell L; Cornelius V; Wilton LV; Shakir SA
    BJU Int; 2009 Feb; 103(4):506-14. PubMed ID: 18990133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.